Since 2017 TTS has been participating in the Transplantation Therapeutics Consortium (TTC), a program of the Critical Path Institute (https://c-path.org/programs/ttc/).
TTC is a public-private collaboration between the transplant community, including industry, academia, professional societies, and regulatory agencies. TTC’s mission is to accelerate the pace of medical product development for transplant recipients with a focus on obtaining regulatory agency endorsement of new medical products. TTS members, Roslyn Mannon and Randy Morris have been representing TTS in this forum. TTC’s initial work has been on endorsing the iBox Scoring System (Composite Biomarker Panel) for acceptance by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a surrogate endpoint to accelerate the pace of drug development in the field of kidney transplantation.
Glycocalyx Damage Within Human Liver Grafts Correlates With Graft Injury and Postoperative Graft Function After Orthotopic Liver TransplantationDestruction of the endothelial glycocalyx has been observed within lung and kidney grafts during ischemic organ preservation. We aimed to quantify glycocalyx damage within human liver grafts after organ preservation and correlate the results with graft injury and postoperative graft function in patients undergoing orthotopic liver transplantation (OLT).
Challenges in the Management of Kidney Allograft Herniation With a Single-stage Pedicled Anterolateral Thigh FlapWound complications are the most common surgical complication after kidney allograft transplantation. Total wound rupture exposing the entire kidney is a rare and not well-described event. We present a successful treatment of this complication in a patient admitted to our unit. A single-stage procedure was performed combining debridement and reconstruction with a pedicled anterolateral thigh flap and an iliotibial band transferring. A short literature review is performed comparing the different treatment strategies and results.
TTS and ILTS congratulates these teams and wishes them every success in their collaborations over the next six years and beyond.
This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.
This activity is meant to improve clinician’s identification of resistant/refractory cytomegalovirus (CMV) and update them on newly approved treatment strategies for resistant/refractory CMV in solid organ transplant (SOT) patients.
CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.Upon completion of this activity, participants should be better able to:
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)
This survey focuses on issues encountered by physicians in day-to-day decision-making.
Your responses will aid TTS in developing strategies, programs and resources to improve access and transparency in transplantation, emphasizing increasing deceased donor organ transplantation.
The information collected will also aid the work TTS is doing as part of our World Health Organization collaboration.
All responses will be kept confidential and anonymous.
The Transplantation Society
740 Notre-Dame Ouest
Montréal, QC, H3C 3X6